Diabetic Retinopathy and Glucagon-Like Peptide-1 Agonists

What’s the latest, and what are the implications for practice?

By: Sherrol A. Reynolds, OD, FAAO, FNAP, FORS

Optometric Management May 1, 2025 Vol 60(4), Issue May 2025 Page(s): 10,11

-0:00/0:00

Sherrol A. Reynolds

Specialties: Optometry

Bio: Sherrol A. Reynolds, OD, FAAO, FNAP, FORS, is an optometrist who writes on diabetic retinopathy and clinical implications for eye care practice. In Optometric Management, Reynolds has addressed the relationship between glucagon-like peptide-1 agonists and diabetic retinopathy, including considerations for monitoring patients with diabetes and coordinating care with primary care physicians.

PentaVision

Optometric Management

Diabetic Retinopathy and Glucagon-Like Peptide-1 Agonists

Recommendations